StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$6.65+0.95 (+16.67%)

Close on Nov 18, 2026Market cap $12.95MP/E –Yield –

Akari Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Akari Therapeutics's price to book ratio was 0.7× on Nov 11, 2026, against 0.7× a year earlier. Over the last 5 years it ranged from 0.2× to 44.6×, with a median of 5.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.7×+0.3
2025Dec 31, 20250.4×−4.4
2024Jan 31, 20244.8×−0.9
2023Dec 29, 20235.7×+2.3
2022Dec 30, 20223.3×−33.0
2021Dec 31, 202136.3×+29.0
2020Dec 31, 20207.4×+1.9
2019Dec 31, 20195.5×+2.7
2018Dec 31, 20182.8×+0.5
2017Dec 29, 20172.2×+0.2
2016Dec 30, 20162.0×−2.1
2015Dec 31, 20154.1×–

More Akari Therapeutics figures

See a number that looks wrong?